Aditxt (NASDAQ:ADTX – Get Free Report) and Avalo Therapeutics (NASDAQ:AVTX – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.
Profitability
This table compares Aditxt and Avalo Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aditxt | -684,001.00% | -461.78% | -80.55% |
| Avalo Therapeutics | N/A | -88.43% | -73.86% |
Valuation and Earnings
This table compares Aditxt and Avalo Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aditxt | $130,000.00 | 4.44 | -$34.45 million | ($1,387.93) | 0.00 |
| Avalo Therapeutics | $440,000.00 | 698.42 | -$35.13 million | ($5.36) | -3.16 |
Aditxt has higher earnings, but lower revenue than Avalo Therapeutics. Avalo Therapeutics is trading at a lower price-to-earnings ratio than Aditxt, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Aditxt has a beta of 1.49, suggesting that its share price is 49% more volatile than the S&P 500. Comparatively, Avalo Therapeutics has a beta of 0.84, suggesting that its share price is 16% less volatile than the S&P 500.
Analyst Ratings
This is a summary of current ratings and target prices for Aditxt and Avalo Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aditxt | 1 | 0 | 0 | 0 | 1.00 |
| Avalo Therapeutics | 1 | 0 | 9 | 1 | 2.91 |
Avalo Therapeutics has a consensus price target of $32.71, indicating a potential upside of 93.00%. Given Avalo Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Avalo Therapeutics is more favorable than Aditxt.
Institutional and Insider Ownership
15.5% of Aditxt shares are held by institutional investors. Comparatively, 87.1% of Avalo Therapeutics shares are held by institutional investors. 0.0% of Aditxt shares are held by insiders. Comparatively, 3.0% of Avalo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
Avalo Therapeutics beats Aditxt on 12 of the 15 factors compared between the two stocks.
About Aditxt
Aditxt, Inc., a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.
About Avalo Therapeutics
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
Receive News & Ratings for Aditxt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aditxt and related companies with MarketBeat.com's FREE daily email newsletter.
